The Latest Breaking News from Pfizer

Asian shares are trading mixed in the absence of key market-driving news in the region, after a seemingly relentless rally continued on Wall Street

Metsera stock has soared after Pfizer announced a $7.3 billion acquisition, sparking investor buzz. Analysts are now weighing whether the biotech rally has more room to run or if buyers should stay cautious.

Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Here are five “set-and-forget” dividend stocks.

Investors love blue-chip stocks that pay fat dividends, but high yield alone doesn’t guarantee a safe income stream.

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

Back in the 2000s, the American pharmaceutical firm Wyeth was sued by thousands of women who had developed breast cancer after taking its hormone replacement drugs. Court filings revealed the role of “dozens of ghostwritten reviews and commentaries published in medical journals and supplements being used to promote unproven benefits…

Looks like he is running out of things to destroy.